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Rising Rates of Cardiac Rhythm Management Device Infections
in the United States: 1996 through 2003
To the Editor: Clinical indications for cardiac rhythm manage-
ment devices (CRMDs) have expanded dramatically. The impact
of this expansion upon rates of CRMD infection, a complication
of device therapy that often requires system explantation (1), has
not been clearly defined.
We hypothesized that the current growth in implantable car-
dioverter defibrillator (ICD) utilization would impact rates of
CRMD infection, both by expanding and changing the demo-
graphics of the population at risk. We analyzed a nationally
representative database to compare trends in rates of new CRMD
implants with rates of hospitalization for CRMD infection. We
also sought to define the rates of in-hospital mortality associated
with such events.
We collected files from the National Hospital Discharge Survey
(NHDS) from 1996 to 2003. Cases with a primary discharge
diagnosis of pacemaker (PM) or ICD infection (International
Classification of Diseases-9th Revision-Clinical Modification
[ICD-9-CM] code 996.61) were identified. In addition, patients
with device explantation (ICD-9-CM codes 37.77, 37.79, 37.89,
or 37.99) and a primary discharge diagnosis of sepsis (ICD-9-CM
code 038 or 785.59), bacteremia (ICD-9-CM code 790.7), endo-
carditis (ICD-9-CM codes 421.0, 421.9, or 424.90), cellulitis
(ICD-9-CM code 682.9), or fever (ICD-9-CM code 780.6) were
defined as having CRMD infection. New CRMD implantations
were identified by ICD-9-CM procedural codes 377.0 to 377.6.
In order to determine the clinical predictors for in-hospital
mortality among patients with CRMD infection, a control group
with previously implanted PM or ICD who did not have CRMD
infection was identified. This much larger group included patients
with PM or ICD in situ (ICD-9-CM codes V45.01 or V45.02,
respectively) who were discharged with diagnoses other than
CRMD infection. Demographic factors were recorded. Other
characteristics were identified, including presence of diabetes
(ICD-9-CM codes 250.00 to 250.02 or 250.70 to 250.72), renal
failure (ICD-9-CM codes 585, 593.9, or V56.0), and hospital size.
Univariate analysis was performed using 1-way analysis of
variance for continuous variables and the chi-square test for
categoric variables. Multivariate analysis using a binary logistic
regression test was undertaken to determine the independent
predictors of in-hospital mortality. Cases were weighed using the
“weight” variable for derivation of national estimates according to
the NHDS guidelines. A p value of 0.05 was considered
statistically significant.
During the study period, there was a 49% rise in the number of
new CRMD implantations in the U.S., from 159,585 in 1996 to
237,720 in 2003. Most of this increase was driven by ICD
insertions (160% for ICDs vs. 31% for PMs); however, the
absolute numbers of PM implantations remained higher (180,284
for PMs vs. 57,436 for ICDs in 2003). From 1996 through 2003,
there were no significant changes in the demographic characteris-
tics of patients receiving CRMD implantations except that the
proportion of patients receiving an ICD increased significantly
(14% in 1996 vs. 27% in 2003, p  0.001).
In the same period, the number of hospitalizations with CRMD
infection increased 3.1-fold (2.8-fold for PMs and 6-fold for
ICDs). Comparing 1996 with 2003, the increase in numbers of
CRMD-infection-related hospitalizations was 6,720 for PMs and
1,779 for ICDs. Thus numbers of CRMD-infection-related hos-
pitalizations continued to increase out of proportion to rates of
new device implants (Fig. 1).
Cardiac rhythm management device infection conferred a high
in-hospital mortality rate (Table 1). After correcting for age,
gender, race, hospital size, presence of diabetes mellitus or renal
failure, CRMD infection increased the risk of in-hospital death
more than 2-fold (odds ratio [OR] 2.41, p  0.001). Predictors of
death also included older age (OR  1.63 per 20-year increase
in age, p  0.001) and the presence of renal failure (OR  1.76,
p  0.001).
Device infection is an uncommon but devastating complication
of CRMD therapy. We found that rates of hospitalization for
CRMD infection increased faster than rates of CRMD implants
from 1996 through 2003. This disproportionate increase is con-
sistent with the findings of Cabell et al. (2) who demonstrated
accelerating rates of cardiac device infections among Medicare
beneficiaries from 1990 to 1999. Our current data further demon-
strate that the increase in the risk of infection of CRMD devices
is continuing at an accelerated rate.
Reasons for such a disproportionate rise in CRMD infection are
not clear. The recent shift toward ICD utilization for primary
prevention of sudden cardiac death may play a role, primarily due
to the disadvantaged health status of such ICD recipients. Our
data illustrate a dramatic rise in CRMD infection beginning in
Figure 1. Proportional increase in the number of cardiac rhythm management devices (CMRD) implanted and those infected by the year of hospitalization,
normalized to the number of devices implanted and infected in the year 1996, respectively. Note the dramatic increase in device infections compared with
device implantations, particularly after the year 2000.
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2001 and 2002, when early primary prevention ICD trials such as
MADIT (Multicenter Automatic Defibrillator Implantation
Trial) and MUSTT (Multicenter UnSustained Tachycardia Trial)
were being digested and accepted by the scientific community. It
remains unsettled, however, whether ICDs confer a higher infec-
tion risk than PMs (3,4). An indirect effect of expanding ICD
indications could be an increased proportion of implantation by
low volume operators or facilities, a factor that has been linked to
higher rates of mechanical complications and infections (5).
However, this probability cannot be tested using the NHDS
database. It is also possible that greater physician awareness and
improvements in detection and reporting of device-related infec-
tions have contributed to the rise over the study period. Regardless
of the cause, the disproportionate rise in CRMD-related infections
carries significant public health consequences, and further study is
warranted to confirm this trend and to elucidate its causes.
In addition to its morbidity and associated additional health
care resource expenditures, CRMD infection confers high in-
hospital mortality rates. In the late 1990s, Chua et al. (6)
retrospectively studied 117 patients undergoing device extraction
for CRMD infection at a large tertiary care center and found low
all-cause and zero-operative mortality. The recent expansion of
ICD and cardiac resynchronization therapy to patient populations
with a heavier burden of cardiovascular disease may explain the
higher mortality seen with CRMD infection in this analysis.
This study has several important limitations. The NHDS
database, though providing broad national representation, lacks
detailed clinical information. Thus, determination of the mode of
in-hospital death, the specialty of the implanting physicians, and
the identification of the offending organisms are not within the
scope of the NHDS. The validity of the data hinges upon
appropriate coding of ICD-9-CM codes at the time of hospital
discharge. We cannot exclude changes in coding patterns over the
8 years of the study period, for example to improve Medicare
reimbursement for certain diagnoses. Because the NHDS records
hospitalizations, but does not identify individual patients, the true
incidence of CRMD infection cannot be determined.
In conclusion, our results demonstrate a rapid rise in rates of
hospitalization for CRMD-related infection in the U.S. in the
years 2001 through 2003, the last year for which data is currently
available. This morbid and costly complication of CRMD therapy
can be lethal, as evidenced by its associated high rates of in-
hospital mortality. Further research should be undertaken to
confirm these findings, determine the causes of rising rates of
CRMD infections, and to improve therapeutic options for these
important adverse events.
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Letters to the Editor
Questions in
Cardiac Resynchronization
Therapy: Metabolic Implications
With great interest we read the study by Bax et al. (1) relating to
unresolved questions of cardiac resynchronization therapy (CRT).
Many different trials have shown the beneficial effects of CRT
using a variety of quantitative assessments such as the 6-min walk
test, peak oxygen consumption (VO2), New York Heart Associa-
tion (NYHA) functional class, quality-of-life measures, or mor-
tality as primary end points. Among the exercise test variables,
ventilatory efficiency (VE/VCO2) slope is increasingly recognized as
at least as good and possibly an even better prognostic indicator
than peak VO2 (2). Does CRT improve VE/VCO2 slope? So far
only one uncontrolled study has addressed this question, and after
1 to 3 months no improvement was seen. A large body of evidence
shows that chronic heart failure (CHF) affects skeletal muscle
functional capacity and metabolic status (like increased insulin
resistance [3]), which in turn contribute to patient symptoms.
Information on changes of these parameters with CRT would be
relevant in order to shed more light on the mechanisms of
CRT-related improvement of symptomatic status. In CHF pa-
Table 1. Multivariate Predictors of In-Hospital Mortality in
Patients With Cardiac Rhythm Management Devices
OR
95% CI
p ValueLower Upper
Age per 20-yr increase 1.63 1.41 1.89 0.001
Female gender 0.86 0.72 1.03 0.11
Race minorities vs. Caucasians 1.12 0.85 1.48 0.42
Diabetes mellitus 1.03 0.81 1.31 0.82
Renal failure 1.76 1.26 2.47 0.001
Type of device implanted
(ICD vs. PM)
0.78 0.55 1.11 0.17
Hospital size (per 100-bed
increase in size)
1.04 0.97 1.12 0.26
CRMD infection 2.41 1.58 3.66 0.001
CI  confidence interval; CRMD  cardiac rhythm management device; ICD 
implantable cardioverter-defibrillator. OR  odds ratio; PM  pacemaker.
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